EP3302501
COMBINATION OF A PD-1 ANTAGONIST AND CPG-C TYPE OLIGONUCLEOTIDE FOR TREATING CANCER
Status:
EP einkaleyfi: Þýðing ekki lögð innEP appl. date:
26.5.2016EP published:
22.9.2021EP application number:
16804054.1
EPO information:
European Patent Register
Max expiry date:
25.5.2036
Title:
COMBINATION OF A PD-1 ANTAGONIST AND CPG-C TYPE OLIGONUCLEOTIDE FOR TREATING CANCER
Timeline
Today
26.5.2016EP application
22.9.2021EP Publication
Owner
Name:
Merck Sharp & Dohme Corp.Address:
126 East Lincoln Avenue, Rahway, NJ 07065-0907, US
Name:
Surefire Medical, Inc.Address:
d/b/a TriSalus Life Sciences 6272 West 91st Avenue, Westminster, CO 80031, US
Inventor
Name:
YU, YingAddress:
Palo Alto, California 94304, US
Name:
DENKER, Andrew EvanAddress:
Ardmore, PA 19003, US
Name:
SADEKOVA, SvetlanaAddress:
Palo Alto, California 94304, US
Name:
PHAN, Uyen TruongAddress:
Palo Alto, California 94304, US
Name:
KASTELEIN, Robert A.Address:
Palo Alto, California 94304, US
Name:
KAUFMAN, David RossAddress:
North Wales, Pennsylvania 19454, US
Name:
COFFMAN, Robert L.Address:
Berkeley, California 94710-2753, US
Name:
GUIDUCCI, CristianaAddress:
Berkeley, California 94710-2753, US
Name:
JANSSEN, Robert S.Address:
Berkeley, California 94710-2753, US
Priority
Number:
201562168449 PDate:
29.5.2015Country:
US
Number:
201562169309 PDate:
1.6.2015Country:
US
Classification
Categories:
A61K 31/7115, A61K 39/39, A61K 45/06, A61K 9/00, A61N 5/00, C07K 14/435, A61P 35/00